Medicare Extends Interim GLP-1 Coverage Amid Insurer Resistance

The U.S. government has extended a temporary program providing Medicare coverage for GLP-1 weight loss medications, following a failure to reach an agreement with leading health insurers on a permanent payment model. The decision comes as the administration sought to implement a long-term structure for the reimbursement of high-demand drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. However, the proposed model met significant resistance from insurers, who balked at the financial terms and risk profiles associated with the long-term plan. By extending the interim program, the administration ensures that eligible patients continue to have access to these medications in the short term. This prevents an immediate coverage gap that could have occurred had the temporary program expired without a successor. For pharmaceutical giants Novo Nordisk and Eli Lilly, the extension provides continued revenue stability and market penetration within the Medicare population. Conversely, the standoff with insurers highlights the ongoing tension between drug pricing, patient access, and the fiscal sustainability of healthcare coverage for expensive weight-loss therapies.